Trial Profile
A Study to Evaluate the Efficacy of Bortezomib based Multiple Therapeutic Modalities for Donor Specific Antibody Treatment in Patients Who Underwent Lung Transplant.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 21 Aug 2015 New trial record